Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Glaucoma Treatment Market

ID: MRFR/HC/18751-HCR
128 Pages
Vikita Thakur
Last Updated: May 15, 2026
Glaucoma Treatment Market Research Report Information By Disease Type (Open Angle Glaucoma, Angle Closure Glaucoma, Others), By Drug Class (Prostaglandin Analogs, Beta Blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online Pharmacy), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Disease Type (USD Billion) | |
      1. 4.1.1 Open angle glaucoma | |
      2. 4.1.2 Angle closure glaucoma | |
      3. 4.1.3 Others |
    2. 4.2 Healthcare, BY Drug Class (USD Billion) | |
      1. 4.2.1 Prostaglandin analogs | |
      2. 4.2.2 Beta blockers | |
      3. 4.2.3 Adrenergic agonists | |
      4. 4.2.4 Carbonic anhydrase inhibitors | |
      5. 4.2.5 Others |
    3. 4.3 Healthcare, BY Distribution Channel (USD Billion) | |
      1. 4.3.1 Hospital Pharmacy | |
      2. 4.3.2 Retail Pharmacy | |
      3. 4.3.3 Online Pharmacy |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Allergan (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Novartis (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Pfizer (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Bausch Health (CA) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Santen Pharmaceutical (JP) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Aerie Pharmaceuticals (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Merck & Co. (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Glaukos Corporation (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Horizon Therapeutics (IE) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DISEASE TYPE |
    7. 6.4 US MARKET ANALYSIS BY DRUG CLASS |
    8. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    9. 6.6 CANADA MARKET ANALYSIS BY DISEASE TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY DRUG CLASS |
    11. 6.8 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
    14. 6.11 GERMANY MARKET ANALYSIS BY DRUG CLASS |
    15. 6.12 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    16. 6.13 UK MARKET ANALYSIS BY DISEASE TYPE |
    17. 6.14 UK MARKET ANALYSIS BY DRUG CLASS |
    18. 6.15 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    19. 6.16 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
    20. 6.17 FRANCE MARKET ANALYSIS BY DRUG CLASS |
    21. 6.18 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    22. 6.19 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
    23. 6.20 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
    24. 6.21 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    25. 6.22 ITALY MARKET ANALYSIS BY DISEASE TYPE |
    26. 6.23 ITALY MARKET ANALYSIS BY DRUG CLASS |
    27. 6.24 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    28. 6.25 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
    29. 6.26 SPAIN MARKET ANALYSIS BY DRUG CLASS |
    30. 6.27 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY DISEASE TYPE |
    36. 6.33 CHINA MARKET ANALYSIS BY DRUG CLASS |
    37. 6.34 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    38. 6.35 INDIA MARKET ANALYSIS BY DISEASE TYPE |
    39. 6.36 INDIA MARKET ANALYSIS BY DRUG CLASS |
    40. 6.37 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    41. 6.38 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
    42. 6.39 JAPAN MARKET ANALYSIS BY DRUG CLASS |
    43. 6.40 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    50. 6.47 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
    51. 6.48 THAILAND MARKET ANALYSIS BY DRUG CLASS |
    52. 6.49 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    53. 6.50 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
    54. 6.51 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
    55. 6.52 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
    61. 6.58 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
    62. 6.59 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    63. 6.60 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
    64. 6.61 MEXICO MARKET ANALYSIS BY DRUG CLASS |
    65. 6.62 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Disease Type (USD Billion, 2025-2035)

  • Open angle glaucoma
  • Angle closure glaucoma
  • Others

Healthcare By Drug Class (USD Billion, 2025-2035)

  • Prostaglandin analogs
  • Beta blockers
  • Adrenergic agonists
  • Carbonic anhydrase inhibitors
  • Others

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy